Literature DB >> 33820829

Revisiting Current Concepts on the Tolerogenicity of Steady-State Dendritic Cell Subsets and Their Maturation Stages.

Manfred B Lutz1, Ronald A Backer2, Björn E Clausen2.   

Abstract

The original concept stated that immature dendritic cells (DC) act tolerogenically whereas mature DC behave strictly immunogenically. Meanwhile, it is also accepted that phenotypically mature stages of all conventional DC subsets can promote tolerance as steady-state migratory DC by transporting self-antigens to lymph nodes to exert unique functions on regulatory T cells. We propose that in vivo 1) there is little evidence for a tolerogenic function of immature DC during steady state such as CD4 T cell anergy induction, 2) all tolerance as steady-state migratory DC undergo common as well as subset-specific molecular changes, and 3) these changes differ by quantitative and qualitative markers from immunogenic DC, which allows one to clearly distinguish tolerogenic from immunogenic migratory DC.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Year:  2021        PMID: 33820829     DOI: 10.4049/jimmunol.2001315

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

Authors:  Raquel S Laureano; Jenny Sprooten; Isaure Vanmeerbeerk; Daniel M Borras; Jannes Govaerts; Stefan Naulaerts; Zwi N Berneman; Benoit Beuselinck; Kalijn F Bol; Jannie Borst; An Coosemans; Angeliki Datsi; Jitka Fučíková; Lisa Kinget; Bart Neyns; Gerty Schreibelt; Evelien Smits; Rüdiger V Sorg; Radek Spisek; Kris Thielemans; Sandra Tuyaerts; Steven De Vleeschouwer; I Jolanda M de Vries; Yanling Xiao; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2022-07-04       Impact factor: 7.723

2.  Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression.

Authors:  Fang Huang; Zhichao Li; Wenhao Zhang; Jiaqi Li; Siguo Hao
Journal:  Cancer Immunol Immunother       Date:  2022-01-29       Impact factor: 6.630

Review 3.  Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.

Authors:  Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 4.  Targeting DCs for Tolerance Induction: Don't Lose Sight of the Neutrophils.

Authors:  Florianne M J Hafkamp; Tom Groot Kormelink; Esther C de Jong
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

5.  Multi-Tissue Characterization of GILZ Expression in Dendritic Cell Subsets at Steady State and in Inflammatory Contexts.

Authors:  Molène Docq; Mathias Vétillard; Carmen Gallego; Agnieszka Jaracz-Ros; Françoise Mercier-Nomé; Françoise Bachelerie; Géraldine Schlecht-Louf
Journal:  Cells       Date:  2021-11-13       Impact factor: 6.600

Review 6.  Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.

Authors:  Ruoyu Li; Hui Li; Xiaoyan Yang; Huiru Hu; Peidong Liu; Hongbo Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.